Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Loncastuximab tesirine-lpyl | Zynlonta | ADCT-402 | CD19 Antibody 21 | Zynlonta (loncastuximab tesirine-lpyl) is a human anti-CD19 antibody in conjugation with a pyrrolobenzodiazepine (PBD) dimer toxin, which may specifically target CD19-positive tumor cells (Blood 2017 130(Suppl 1):187, PMID: 32012214). Zynlonta (loncastuximab tesirine-lpyl) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (FDA.gov). |
| Mosunetuzumab-axgb | Lunsumio | RG7828|BTCT4465A|RO7030816|BTCT-4465A | CD20 Antibody 26 CD3 Antibody 119 | Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04970901 | Phase I | Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Recruiting | USA | ITA | GBR | ESP | CZE | BEL | 0 |
| NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
CKB BOOST